by Glucose Metabolism Modification in Stressed Neurons Caters to Development of New Drugs
Brain injuries of various types and neurological diseases are one of the main causes of deaths worldwide. Hence, researchers are tapping into opportunities through glucose metabolism modification for the development of new drugs that could revolutionize the treatment of neurological disorders. For instance, Gero Discovery – a supplier of novel therapeutic options for neurodegenerative diseases, announced that they have found a potential drug that can help prevent neuronal deaths with the technique of glucose metabolism modification in stressed neurons. Thus, companies in the neurological disorder drugs market should collaborate with talented researchers to develop new drugs.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111889
Companies in the neurological disorder drugs market are increasing animal testing and obtaining promising results for future use of drugs made with glucose metabolism modification in humans. This new technique has the potential to treat Amyotrophic lateral sclerosis, Alzheimer’s, and traumatic brain injuries, among others, in the market for neurological disorder drugs. As such, companies in the market for neurological disorder drugs are capitalizing on the demand for drugs used in the treatment of Alzheimer’s, since the disorder is estimated to account for the second-highest revenue in the market by 2027.
Innovations in 3D CNS Organoids Revolutionize Neurological Disorder Drugs Market
The Central Nervous System (CNS) drug discovery is largely dependent on traditional approaches related to rodent models or cell-based in vitro models. This practice creates a challenge for drug manufacturers, since species differences between humans and rodents are difficult for the correlation of robust data in neurodevelopmental studies. This explains a modest ~5% CAGR of the neurological disorder drugs market. Hence, companies are advancing in the field of stem cells and 3D CNS organoids, since novel tools have close resemblance to the human brain architecture and functions.
CNS organoids provide innovative opportunities to mimic the human brain physiology and acts as a unique modeling tool for the assessment of normal versus pathological brain. CNS organoids are being highly publicized in the market for neurological disorder drugs for elucidation of mechanisms of neurological disorders. This is evident since the revenue of cerebrovascular disorders is projected to aggressively grow in the market for neurological disorder drugs.
Investors Address Need for Effective CNS Drugs as Companies Research Neuroscience
Several large-cap pharmaceutical companies are partnering with small biotech companies and academic institutes to innovate in CNS drugs, while regulatory bodies are searching for ways to address the void in effective drug development. Companies in the neurological disorder drugs market are increasing R&D in neuroscience, since the U.S. FDA approved Sage Therapeutics Inc.’s first-of-its-kind postpartum depression therapy Zulresso. With the U.S. being one of the leading countries in North America, the neurological disorder drugs market in the region is anticipated for exponential growth. Moreover, further innovations in CNS drugs, the neurological disorder drugs market is estimated to reach a value of ~US$ 112 Bn by the end of 2027.
Get a glimpse of the in-depth analysis through our Report Brochure
The field of neuroscience is undergoing a phase of renaissance. This is evident since the FDA stated that organization is witnessing an explosion of new scientific knowledge addressing difficult-to-treat CNS disorders. Investors in the market for neurological disorder drugs are taking note of the FDA’s shifting attitude toward tough-to-treat CNS disorders.
Activating Wild Type GCase Holds Promising Potential for Treatment of Parkinson’s Disease
Companies in the neurological disorder drugs market are adopting new therapeutic approaches for the treatment of the Parkinson’s disease. They are increasing research to understand genetic risk factors associated with the disease for improved drug development. Hence, alterations in the GBA1 gene is emerging as a promising approach for drug development. However, mutations in the gene may result in defects of GCase (glucocerebrosidase) enzymes. Hence, companies in the neurological disorder drugs market are focusing on activating wild type GCase for the development of new drug compounds that can be used in the treatment of Parkinson’s.
The market for neurological disorder drugs is undergoing a change with increased experiments associated with the activation of wild type GCase, resulting in therapeutic benefits among patients.
Analysts’ Viewpoint
Antiepileptic and anticholinergic drugs are projected to witness exponential growth in demand in the neurological disorder drugs market. Since big pharmaceutical companies are exiting the neurology space, small biotech companies are stepping up to introduce new neurology drugs. However, clinical trials in neuroscience are expensive to run and the success rate is much lower than that of other disease indications. Hence, companies should identify new genes that lead to new pathways in drug delivery for Alzheimer’s and Parkinson’s. Apart from North America, companies should invest in Asia Pacific since the region is projected for exponential growth during the forecast period. Influx of money flow in the field of CNS is one of the key drivers contributing to market growth.
Neurological Disorder Drugs Market: Overview
Neurological disorder drugs can be used for various diseases such as epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others
Around 450 different medications are available for the treatment of neurologic disorders. The epilepsy segment dominated the global neurological disorder drugs market in 2018. Growth of the segment can be attributed to increase in demand for the treatment of cerebrovascular diseases such as stroke.
Neurological Disorder Drugs Market Drivers
Increase in the geriatric population leads to manifestation of various neurology disorders, which, in turn, fuels the global market. Cerebrovascular diseases such as stroke and migraine are high in countries such as Germany, the U.K., and Italy in all age groups. France, Sweden, Greece, Denmark, and Russia have high incidence rate of cerebrovascular diseases in people aged between 45 and 84. A study published in NCBI in 2018 indicated that prevalence of stroke was 7.67% among adults aged 65 years and above in Singapore.
Rise in Research & Development Programs
Demand for neurological disorder drugs and competition between key players is increasing. Market players focus on molecule growth, with key technological improvements in drugs in order to fulfil customer demand.
In March 2019, the U.S. FDA approved Novartis AG’s Mayzent for the treatment of adults with relapsing forms of multiple sclerosis, including SPMS with active disease, relapsing remitting multiple sclerosis (RRMS), and clinically isolated syndrome (CIS)
Market Segmentation: Neurological Disorder Drugs Market
Based on disorder, the global neurological disorder drugs market has been divided into epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others
In terms of drug class, the global neurological disorder drugs market has been classified into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others
Based on distribution channel, the global neurological disorder drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies
Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.
Regional Overview: Neurological Disorder Drugs Market
In terms of region, the global neurological disorder drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, along with their CAGRs for the period from 2019 to 2027
The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process
Major Players in Neurological Disorder Drugs Market
The report concludes with the company profiles section that includes key information about the major players in the market
Leading players analyzed in the report are
- Novartis AG
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Pfizer
- Bayer AG
- Boehringer Ingelheim GmbH
- AstraZeneca
- Teva Pharmaceutical Industries
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Amgen, Inc.
- UCB S.A.
- Eli Lilly and Company
- Biogen
Key Questions Answered in Neurological Disorder Drugs Market Report
- What is the sales/revenue generated by neurological disorder drugs across all regions during the forecast period?
- What are the opportunities in the global neurological disorder drugs market?
- What are the major drivers, restraints, opportunities, and threats in the global market?
- Which region is set to expand at the fastest CAGR during the forecast period?
- Which disorder segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Neurological Disorder Drugs Market – Segmentation
Disorder
- Epilepsy
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Cerebrovascular Diseases
- Others
Drug Class
- Anticholinergi
- Antiepileptic
- Antipsychotic
- Hypnotic & Sedatives
- Analgesics
- Antihypertensive
- Anticoagulants
- Others
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111889/2900
